Partnership Announcement: AI software integration between EnsoData and Parachute Health aims to connect sleep disorder diagnosis to therapy prescription.
Aeroflow and EnsoData usher in a new era in personalized sleep apnea care, population health management, and patient coaching with AI-powered predictive analysis of CPAP monitoring data.
EnsoData announces its FDA-cleared diagnostic AI analysis and sleep scoring solution, EnsoSleep, earned stage-specific autoscoring software certification from the American Academy of Sleep Medicine (AASM).
EnsoData achieved FDA 510(k) clearance for groundbreaking technology that enables AI-powered sleep diagnosis using FDA-cleared pulse oximetry (pulse ox) devices.
EnsoData and React Health announced a strategic collaboration to optimize PAP adherence support for patients with sleep apnea using EnsoData’s AI technology.
EnsoData Ranks Among Highest-Scoring Businesses on Inc. Magazine’s 2023 List of Best Workplaces, marking third consecutive year on the list.
EnsoData Applies AI to Address Health Concerns for 1,000,000 Patients Worldwide, a milestone reached in May 2023.
EnsoData has appointed Dr. Nathaniel Watson as New Chief Medical Officer, expanding its clinical sleep expertise.
EnsoData’s new funding, coupled with new partnerships and an executive hire, promise rapid growth and accelerated delivery of its validated AI solution for sleep medicine.
EnsoData receives FDA 510(k) clearance of latest sleep center tools to enhance patient care and experience; expands into pediatrics and adds to home testing capabilities.